These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16455599)

  • 21. Targeting insulin-like growth factor I with 10-23 DNAzymes: 2'-O-methyl modifications in the catalytic core enhance mRNA cleavage.
    Fokina AA; Meschaninova MI; Durfort T; Venyaminova AG; François JC
    Biochemistry; 2012 Mar; 51(11):2181-91. PubMed ID: 22352843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of hepatitis B virus X gene expression by 10-23 DNAzymes.
    Hou W; Ni Q; Wo J; Li M; Liu K; Chen L; Hu Z; Liu R; Hu M
    Antiviral Res; 2006 Dec; 72(3):190-6. PubMed ID: 16930733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of core-modified 10-23 DNAzymes against HCV.
    Robaldo L; Berzal-Herranz A; Montserrat JM; Iribarren AM
    ChemMedChem; 2014 Sep; 9(9):2172-7. PubMed ID: 25079672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cleavage of telomerase RNA component by two DNAzymes and their effects on expression of two apoptosis-related genes in human mammary cancer cells].
    Zhao JM; Li MY; Yang Z; Li Z; Zhang Y
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):638-42. PubMed ID: 15958297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic potential of siRNA and DNAzymes in cancer.
    Karnati HK; Yalagala RS; Undi R; Pasupuleti SR; Gutti RK
    Tumour Biol; 2014 Oct; 35(10):9505-21. PubMed ID: 25149153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. iNOS-targeted 10-23 DNAzyme reduces LPS-induced systemic inflammation and mortality in mice.
    Verma N; Tripathi SK; Chaudhury I; Das HR; Das RH
    Shock; 2010 May; 33(5):493-9. PubMed ID: 19823115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific repression of mutant K-RAS by 10-23 DNAzyme: sensitizing cancer cell to anti-cancer therapies.
    Yu SH; Wang TH; Au LC
    Biochem Biophys Res Commun; 2009 Jan; 378(2):230-4. PubMed ID: 19014906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNAzymes and their therapeutic possibilities.
    Chan CW; Khachigian LM
    Intern Med J; 2009 Apr; 39(4):249-51. PubMed ID: 19402864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospects for antiviral ribozymes and deoxyribozymes.
    Peracchi A
    Rev Med Virol; 2004; 14(1):47-64. PubMed ID: 14716691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNAzyme-mediated silencing of ornithine decarboxylase.
    Ackermann JM; Kanugula S; Pegg AE
    Biochemistry; 2005 Feb; 44(6):2143-52. PubMed ID: 15697240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ribozymes, DNAzymes and small interfering RNAs as therapeutics.
    Sioud M; Iversen PO
    Curr Drug Targets; 2005 Sep; 6(6):647-53. PubMed ID: 16178798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA Catalysis: The Chemical Repertoire of DNAzymes.
    Hollenstein M
    Molecules; 2015 Nov; 20(11):20777-804. PubMed ID: 26610449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiogenic inhibition mediated by a DNAzyme that targets vascular endothelial growth factor receptor 2.
    Zhang L; Gasper WJ; Stass SA; Ioffe OB; Davis MA; Mixson AJ
    Cancer Res; 2002 Oct; 62(19):5463-9. PubMed ID: 12359754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tetrahedral DNA Nanostructure-Delivered DNAzyme for Gene Silencing to Suppress Cell Growth.
    Meng L; Ma W; Lin S; Shi S; Li Y; Lin Y
    ACS Appl Mater Interfaces; 2019 Feb; 11(7):6850-6857. PubMed ID: 30698411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delivery of therapeutic RNA-cleaving oligodeoxyribonucleotides (deoxyribozymes): from cell culture studies to clinical trials.
    Fokina AA; Chelobanov BP; Fujii M; Stetsenko DA
    Expert Opin Drug Deliv; 2017 Sep; 14(9):1077-1089. PubMed ID: 27892730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Divergent effects of arginine vasopressin and angiotensin II on proliferation and expression of the immediate early genes c-fos, c-jun and Egr-1 in cultured rat glomerular mesangial cells.
    Schulze-Lohoff E; Köhler M; Fees H; Reindl N; Sterzel RB
    J Hypertens; 1993 Feb; 11(2):127-34. PubMed ID: 8385171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inability of DNAzymes to cleave RNA in vivo is due to limited Mg[Formula: see text] concentration in cells.
    Victor J; Steger G; Riesner D
    Eur Biophys J; 2018 May; 47(4):333-343. PubMed ID: 29248953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design of nuclease resistant protein kinase calpha DNA enzymes with potential therapeutic application.
    Sioud M; Leirdal M
    J Mol Biol; 2000 Feb; 296(3):937-47. PubMed ID: 10677293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of helical structures formed by the binding arms of DNAzymes and their substrates on catalytic activity.
    Ota N; Warashina M; Hirano K; Hatanaka K; Taira K
    Nucleic Acids Res; 1998 Jul; 26(14):3385-91. PubMed ID: 9649623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNAzymes: from creation in vitro to application in vivo.
    Achenbach JC; Chiuman W; Cruz RP; Li Y
    Curr Pharm Biotechnol; 2004 Aug; 5(4):321-36. PubMed ID: 15320762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.